At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Market Closed 11-01 16:00:00 EDT
18.27
+1.12
+6.53%
盘后18.27
+0.000.00%
18:53 EDT
High18.62
Low16.87
Vol1.09M
Open17.39
D1 Closing17.15
Amplitude10.20%
Mkt Cap1.25B
Tradable Cap1.02B
Total Shares68.29M
T/O19.85M
T/O Rate1.96%
Tradable Shares55.66M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.